Previous 10 | Next 10 |
2023-12-14 10:33:42 ET More on Amgen Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks Amgen: Buy In Stable Fundamental And Technical Price Growth Amgen gets FDA pr...
2023-12-12 14:34:38 ET More on Eli Lilly, Novartis, etc. Novartis: Post Investor Day, Higher Guidance Priced In Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Co...
2023-12-11 13:57:54 ET More on MorphoSys MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating) Mo...
2023-12-11 13:09:09 ET More on Keros Therapeutics Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Financial information for Keros Therapeutics For further details see: Keros falls after mid-stage d...
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) PR Newswire APPLY-PNH extension data show that continuous Fabhalta ...
2023-12-10 13:48:00 ET On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most technological group of cancer medicines produced to date. Now, drugma...
2023-12-06 10:11:00 ET More on TG Therapeutics TG Therapeutics: Trying To Fill The Gap Back To $20 TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript TG Therapeutics: Q3 Earnings Spike Hard To Explain Given Rival's Numbers TG Therapeutics gains aft...
2023-12-06 05:57:50 ET More on Novartis Novartis: Post Investor Day, Higher Guidance Priced In Novartis AG (NVS) 10th Annual ESG Investor Event Conference (Transcript) Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028 Blackstone said...
2023-12-06 04:37:12 ET More on Merck KGaA Merck KGaA (MKGAF) Q3 2023 Earnings Call Transcript Merck KGaA: Company With A Potential Upside Exscientia climbs as Merck KGaA joins AI drug discovery Historical earnings data for Merck KGaA Dividend scorecar...
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH PR Newswire Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...